Biosimilars - Articles and news items

Biosimilar medicines: Dramatic increase in patient access across Europe

Industry news / 23 May 2017 / Niamh Marriott, Junior Editor

Biosimilar medicines have dramatically increased patient access to biological medicines, according to the recently published QuintilesIMS report…


Biosimilars: the future of Pharma? An interview with Boehringer Ingelheim

Blog, Z Homepage promo / 3 May 2017 / Ivan Blanarik, Senior Vice President and Head of Therapeutic Area Biosimilars at Boehringer Ingelheim

With biosimilars expected to account for 10% of the total biologics market by 2020, we caught up with Boehringer Ingelheim’s Senior VP to find out more…

Sandoz proposed biosimilars recommended for EU approval

Industry news / 25 April 2017 / Niamh Marriott, Junior Editor

CHMP has adopted positive opinions, separately recommending the approval of both Sandoz’s biosimilar rituximab and biosimilar etanercept in Europe…


Global trade bodies issue guidance on biosimilar switching

Industry news / 9 March 2017 / European Pharmaceutical Review

EFPIA, EBE and IFPMA issue joint guidance for prescribers on switching between original reference biologics and biosimilars…

Biosimilars create opportunities for sustainable cancer care

Blog, Z Homepage promo / 22 February 2017 / Professor Josep Tabernero, Chair of the ESMO Cancer Medicines Working Group

Dr Josep Tabernero explains the benefits of biosimilars, showing how they can create sustainable, safe and affordable access to medicine globally…

FDA to review Mylan and Biocon’s biosimilar application

Industry news / 17 February 2017 / Niamh Marriott, Digital Editor

The US Food and Drug Administration (FDA) has accepted Mylan and Biocon’s biologics license application for MYL-1401H, a proposed biosimilar to Neulasta…

FDA accepts Mylan and Biocon’s biosimilar biologics license application

Industry news / 12 January 2017 / Niamh Marriott, Digital Editor

This product is a proposed biosimilar to branded trastuzumab, which is indicated to treat certain HER2-positive breast cancers…

B is for Biosimilars

Blog / 15 November 2016 / Niamh Louise Marriott, Digital Content Producer

B is for Biosimilar – the next instalment of our daily pharmaceutical alphabet bringing you up to date with all the latest news and research on the subject of biosimilars.

Mabion sign supply and commercialisation agreement with Mylan

Industry news / 10 November 2016 / Niamh Louise Marriott, Digital Content Producer

Mabion signed a long-term development and commercialisation agreement with Mylan Ireland a wholly owned subsidiary of Mylan N.V. for its biosimilar…

Mylan and Biocon submit FDA application for Trastuzumab biosimilar

Industry news / 9 November 2016 / Niamh Louise Marriott, Digital Content Producer

Mylan and Biocon have submitted a biologics license application for MYL-1401O, a proposed biosimilar trastuzumab, to the FDA through the 351(K) pathway…

Biosimilars: litigation outlook

Issue 5 2016 / 20 October 2016 / Dominic E. Adair, Bristows LLP

In the Foreword article contributed by Consultant David P. Elder in Issue 3, 2016 of European Pharmaceutical Review, entitled ‘Biosimilars: future prospects’, Dr Elder concluded that it is likely that biosimilars will become increasingly established in both Europe and the United States and that in addition to proteins and peptides, biosimilar monoclonal antibodies (mABs) will […]

Pharmaceutical patents: Clear the way but careful where you tread

Blog, Z Homepage promo / 27 September 2016 / Dominic Adair and Emma Muncey, Bristows

Top litigators Dominic Adair and Emma Muncey review patent court cases to identify the legal steps you should take when marketing a biosimilar…


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...